Show simple item record

Final ALTA-1 results of brigatinib (BRG) and crizotinib (CRZ) in ALK inhibitor-naive non-small cell lung cancer (NSCLC)

dc.contributor.authorGriesinger, F.
dc.contributor.authorCamidge, D. R.
dc.contributor.authorKim, H. R.
dc.contributor.authorAhn, M. J.
dc.contributor.authorYang, J. C.
dc.contributor.authorHan, J. Y.
dc.contributor.authorHochmair, M.
dc.contributor.authorLee, K. H.
dc.contributor.authorDelmonte, A.
dc.contributor.authorGarcia, C. M. R.
dc.contributor.authorKim, D. W.
dc.contributor.authorFelip, E.
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpira, A.
dc.contributor.authorThomas, M.
dc.contributor.authorGettinger, S.
dc.contributor.authorTiseo, M.
dc.contributor.authorLin, H.
dc.contributor.authorLiu, Y.
dc.contributor.authorZhang, P.
dc.contributor.authorPopat, S.
dc.date.accessioned2022-11-30T10:21:34Z
dc.date.available2022-11-30T10:21:34Z
dc.date.issued2022en
dc.identifier.citationGriesinger F, Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, et al. Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC). Oncology Research and Treatment. 2022 Sep;45(SUPPL 2):103-4. PubMed PMID: WOS:000864724100196.en
dc.identifier.urihttp://hdl.handle.net/10541/625841
dc.titleFinal ALTA-1 results of brigatinib (BRG) and crizotinib (CRZ) in ALK inhibitor-naive non-small cell lung cancer (NSCLC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentPius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Deutschlanden
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record